EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? - Wikidata - awgldk - TriplyDB

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

http://www.wikidata.org/entity/Q39340502

about

MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.Targeting cholangiocarcinoma.Patient derived organoids to model rare prostate cancer phenotypes.Transcriptomic and functional network features of lung squamous cell carcinoma through integrative analysis of GEO and TCGA data Ubiquitin Regulation: The Histone Modifying Enzyme's Story

P2860

Q48146766-25094821-10A7-40DA-A575-3A95887DE75F Q52349529-BB904376-456C-4FB8-9F56-3C1093D340A0 Q52757760-C0E1B09A-C6C0-468A-8062-F82EA8916187 Q55367999-195BF4FE-5AFE-4EB5-8BCA-457E2706CEE1 Q58116294-46CED361-D449-4BF7-B17C-A9E1C537CCCC Q58700177-4CFE003F-9FD7-41D5-8438-2B178DC14C00

P2860

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

http://www.wikidata.org/entity/Q39340502

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

@en

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

@nl

type

label

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

@en

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

@nl

prefLabel

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

@en

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

@nl

P1433

Q39340502-1F6D641A-C8DA-4BC1-AB57-9798644EED3E

P1476

Q39340502-D34087FE-D591-45C8-899F-0F1805F7A23D

P2093

Q39340502-1A346788-B0BF-49DB-B4A5-92DF1E154652

Q39340502-4703E8C9-8A83-40F3-B747-5434C21D9253

Q39340502-5C7262FA-8327-4144-8308-46F6F60EA173

Q39340502-9443CAFA-59FA-40FE-B1BA-4D465E299C2C

Q39340502-9674C4EA-69B3-4F8A-B5ED-C943496EA2E0

Q39340502-B319EDB7-5D23-4845-A06C-2710CD531800

Q39340502-D6280F47-5940-486D-91B1-4BB5CF621CFB

P275

Q39340502-4DBBF305-DCB2-4F7F-A74C-5D10D261E6C2

P2860

Q39340502-00553ED9-C97C-44BC-A7B9-03A2D1600C44

Q39340502-00580B19-D694-4053-B0F9-A23BF9229C35

Q39340502-01CCA135-FE40-4FA1-A5A5-60E08E202AD7

Q39340502-04BBC5E5-0C62-4922-A1F0-4F69D9FF8AEA

Q39340502-0586023A-E508-42DF-9B40-1A314224737D

Q39340502-062C84BF-0A44-4529-86A4-6F07D669C2FC

Q39340502-06B4ECD7-184B-4267-8D40-A28B6EDC1A19

Q39340502-07D142EE-5A3E-40FA-BB79-36423B75DFF9

Q39340502-0843BB5A-27CA-4D73-AE2F-DECF02CA8D9C

Q39340502-086B4652-EB2E-489E-88EF-1278314E1EC5

P31

Q39340502-D6B5E381-0355-490F-88B1-AB377A5B732F

P356

Q39340502-6F45EBF6-6285-4A3A-9F5D-A996CCC54B86

P407

Q39340502-05AA2D9B-BBE1-4374-B4D4-33751A211A50

P433

Q39340502-578DEE00-59FD-4C7B-B9F3-2DB17D707719

P478

Q39340502-F8E92290-2E1E-4C8B-98ED-56FD38C7BE29

P50

Q39340502-B2649EDD-8314-4AED-B38D-327B5074EF2A

P5008

Q39340502-3144984E-0B6E-4700-BB7E-FEA6226031F8

P577

Q39340502-CF71CB39-D41D-4D5F-8012-85C1F5530170

P698

Q39340502-837D2BC0-18CE-48A3-9B6E-E9CAD97A3CF3

P921

Q39340502-17E25EDD-418F-4D36-A71C-C8FFFF45B0EE

Q39340502-29265E9D-05F3-4005-9523-1B2E36D05A48

Q39340502-52B9FD0C-AEDB-4903-BFCF-47BE388E6136

Q39340502-65A76CE7-17BA-4F96-9E98-BE546FBDC3BE

Q39340502-8513C979-7095-49EE-BBA3-F5E216751282

Q39340502-D6F9DE8D-E6D9-4CF5-A1B8-CF12BF734FD7

Q39340502-F55E1509-6E76-4231-9A7A-B0E7ED83F500

P932

Q39340502-97EED30A-4D43-47FA-8A86-7CD55920F65A

P356

P1433

International Journal of Molecular Sciences

P1476

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

@en

P2093

Cheng-Ming Peng

http://www.w3.org/2001/XMLSchema#string

Chia-Yuan Lin

http://www.w3.org/2001/XMLSchema#string

Ke-Sin Yan

http://www.w3.org/2001/XMLSchema#string

Shou-Chun Lee

http://www.w3.org/2001/XMLSchema#string

Tan-Wei Liao

http://www.w3.org/2001/XMLSchema#string

Wing P Chan

http://www.w3.org/2001/XMLSchema#string

Yi-Jui Liu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells

The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation

The polycomb group protein EZH2 is required for mammalian circadian clock function

A landscape of driver mutations in melanoma

miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis

Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Comprehensive molecular characterization of human colon and rectal cancer

Comprehensive molecular portraits of human breast tumours

P31

scholarly article

P356

10.3390/IJMS18061172

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Ruey-Hwang Chou

P5008

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28561778

http://www.w3.org/2001/XMLSchema#string

P921

nuclear protein

transcription factor

regulation of gene expression

macromolecular substances

P932

5485996

http://www.w3.org/2001/XMLSchema#string